Lila Sciences
Lila Sciences raises $200M Series A at $800M valuation
Lila Sciences: Series A Funding Round
Lila Sciences has successfully raised $200M in Series A funding, reaching a valuation of $800M.
Company Overview
Develops AI-powered platform for accelerating therapeutic antibody discovery
Funding Details
The Series A round was led by Foresite Capital, with participation from Perceptive Advisors.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2023
- Employees: 80+
- Category: Biotech
Investment
Lila Sciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series A
- Perceptive Advisors: Verified investor in Series A
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free